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Background: Overt chronic metabolic acidosis in patients with chronic kidney disease develops after a drop of
glomerular filtration rate to less than approximately 25 mL/min/1.73 m2. The pathogenic mechanism seems to be a
lack of tubular bicarbonate production, which in healthy individuals neutralizes the acid net production. As shown
in several animal and human studies the acidotic milieu alters bone and vitamin D metabolism, induces muscle
wasting, and impairs albumin synthesis, aside from a direct alteration of renal tissue by increasing angiotensin II,
aldosteron and endothelin kidney levels. Subsequent studies testing various therapeutic approaches in very
selected study populations showed that oral supplementation of the lacking bicarbonate halts progression of
decline of renal function. However, due to methodological limitations of these studies further investigations are of
urgent need to ensure the validity of this therapeutic concept.
Methods/Design: The SoBic-study is a single-center, randomized, controlled, open-label clinical phase IV study
performed at the nephrological outpatient service of the Medical University of Vienna. Two-hundred patients
classified to CKD stage 3 or 4 with two separate measurements of HCO3
- of <21 mmol/L will be 1:1 randomized to
either receive a high dose of oral sodium bicarbonate with a serum target HCO3
- level of 24 ± 1 mmol/L or receive a
rescue therapy of sodium bicarbonate with a serum target level of 20 ± 1 mmol/L. The follow up will be for two
years. The primary outcome is the effect of sodium bicarbonate supplementation on renal function measured by
means of estimated glomerular filtration rates (4-variable-MDRD-equation) after two years. Secondary outcomes are
change in markers of bone metabolism between groups, death rates between groups, and the number of subjects
proceeding to renal replacement therapy across groups. Adverse events, such as worsening of arterial hypertension
due to the additional sodium consumption, will be accurately monitored.
Discussion: We hypothesize that sufficiently balanced acid–base homeostasis leads to a reduction of decline of
renal function in patients with chronic kidney disease. The concept of an exogenous bicarbonate supplementation
to substitute the lacking endogenous bicarbonate has existed for a long time, but has never been investigated
sufficiently to state clear treatment guidelines.
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Chronic kidney disease (CKD) occurs in approximately
one in ten persons worldwide and represents not only a
medical challenge but also a great socioeconomic burden.
Major efforts have been made to investigate treatment
options aiming to slow progression to end-stage renal
disease (ESRD) and, subsequently, to reduce mortality in
kidney patients. A renin-angiotensin system blockade
with either angiotensin-I-converting enzyme inhibitors or
angiotensin-II-receptor antagonists slows the progression
of decline in renal function [1-5]. However, further thera-
peutic interventions have not shown any benefits [6-10].
The comprehensive summery by Fink et al. underscores
the lack of evidence-based treatment concepts in CKD
and even calls screening and monitoring for early-stage
CKD into question [11].
Overt chronic metabolic acidosis in CKD patients
develops after a drop in glomerular filtration rate (GFR)
to less than approximately 25 mL/min/1.73 m2. The
pathogenic mechanism seems to be a lack of tubular
bicarbonate production, which in healthy individuals
neutralizes the acid net production. As shown in several
animal and human studies the acidotic milieu alters
bone and vitamin D metabolism [12], induces muscle
wasting [13], and impairs albumin synthesis [14], in
addition to other detrimental effects [15,16]. Expe-
riments in rats suggest that even in the earlier stages of
CKD with serum bicarbonate levels within normal
limits, increased per-nephron acidification occurs to
obviate overt metabolic acidosis [17]. Investigations to
elucidate the contribution to the progression of CKD
itself have provided contradictory results [18-20]. How-
ever, there is evidence that the alternative complement
system is activated by increased tubular ammonia
production [21] and that endothelin, angiotensin II and
aldosteron kidney concentrations are increased as a dir-
ect result of distal nephron acidification [17,20,22].
Taken together, these alterations induce tubulointerstitial
scarring in the long term.
The results of several retrospective studies conducted in
different types of populations showed clear associations
between acid–base imbalance and increased mortality
[23,24]. Above all is the recently published analysis of the
CKD registry of the Cleveland Clinic health care provider
in 41,749 patients with CKD stage III and IV (estimated
(e) GFR of 60 to 15 mL/min/1.73 m2, measured by the
Chronic Kidney Disease Epidemiology Collaboration
equation). Adjusted for several covariates the all-cause
mortality for subjects with a low serum bicarbonate level
(<23 mmol/L) is 23% higher than for those with a level
within the normal range (23 to 32 mmol/L) [25].
The first prospective studies in closely selected study pop-
ulations [26] using various therapeutic interventions [27]
and endpoints revealed beneficial effects. In particular, deBrito-Ashurst et al. showed that sodium bicarbonate
supplementation in patients with CKD stage IV slows the
decline in renal function, although the study comprised
some seriousmethodological limitations [28].
In line with the aforementioned studies we assume
that a sufficiently balanced acid–base status leads to a
reduction in the decline of renal function in patients
with CKD. Bicarbonate is necessary to counterbalance
acid net production arising from protein metabolism
and acid-rich diets. Thus, the intervention of exogenous
bicarbonate supplementation to substitute the lacking
endogenous bicarbonate would appear to be rational.
This simple concept has existed for a long time, but has
never been investigated sufficiently to state clear treat-
ment guidelines for physicians. Furthermore, including
patients with both moderate and severe grades of renal
impairment represents a novel and comprehensive ap-
proach. Thus, conclusions drawn by results of this study




The SoBic study is a single-center, randomized, controlled,
stratified, open-label clinical phase IV study and will be
performed at the Nephrological outpatient service of the
Medical University of Vienna. From the beginning of
October 2013, 200 subjects with CKD stage III and IV and
chronic metabolic acidosis will be randomized to either
receive a high dose of oral sodium bicarbonate with a
serum target HCO3
- level of 24 ± 1 mmol/L or receive a
rescue therapy of sodium bicarbonate, if necessary, with a
serum target level of 20 ± 1 mmol/L. The follow up period
will be 2 years. The ethics committee of the Medical
University of Vienna and the Austrian Competent Authority
approved the study. The study is registered at the European
Union Drug Regulating Authority (EUDRACT Number:
2012-001824-36; https://www.clinicaltrialsregister.eu) and
will be conducted in accordance with the current version
of the Declaration of Helsinki [29]. All study subjects will
be appropriately insured and are required to give written
informed consent before any study action is taken. Data
will be stored in the Clincase version 2.6.0.33 clinical trial
system (Quadratek Data Solutions Ltd, London, United
Kingdom. Data structure design is developed by the
science support work group of AKIM (Allgemeines
Krankenhaus Informations Management) at the Center of
Medical Statistics, Informatics and Intelligent Systems.
The software provides advanced data management and
data preparation tools for statistic evaluation. The web-
based electronic case report forms allow efficient user
handling and thus, error avoidance. In accordance with
the Good Clinical Practice (GCP) guidelines an independ-
ent person will periodically perform data monitoring [30].
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dated Standards of Reporting Trials (CONSORT) 2010
guidelines [31].
Participants
The study population will comprise incident and prevalent
patients with CKD from the outpatient service of a tertiary
care facility. Patients classified as having CKD stage III
or IV, and two separate measurements of HCO3
- of
<21 mmol/L (at least 1 day apart) will be included in the
study. Patients fulfilling the inclusion criteria, who are
already receiving alkali treatment, can be included after a
wash-out phase of 4 weeks. The inclusion criteria are age
over 18 years, renal function (measured by eGFR calcu-
lated by the four-variable Modification of Diet in Renal
Disease (MDRD) study equation) between 60 and 15 mL/
min/1.73 m2, venous serum HCO3
- of <21 mmol/L on two
consecutive measurements (at least 1 day apart), and for
the patient to be in a stable clinical condition. Patients with
malignant disease or within 5 years of successful treatment
of malignant disease (except dermal malignancies and
carcinoma in situ of the cervix declared to be cured), and
patients with morbid obesity (body mass index >40 kg/m2),
chronic inflammation (C reactive protein >10 mg/dL) or
taking immunosuppressive therapy of any kind, poorly
controlled blood pressure (>150/90 mmHg despite the use
of four agents), overt congestive heart failure, or known
peanut or soy allergy, will be excluded from the study.
With respect to concomitant medication, various drugs
are known to induce metabolic acidosis [32]. However,
most relevant with regard to the planned study are the
phosphate binder sevelamer hydrochloride and potassium-
sparing diuretics. Other agents known to neutralize meta-
bolic acidosis, such as calcium citrate, sodium citrate and
calcium carbonate are not allowed.
Laboratory measurements
Serum creatinine will be determined by means of the
Jaffe method (reference range <1.2 mg/dL, mg/dL ×
88.4 = μmol/L). Bicarbonate measurements will be per-
formed in venous blood samples and determined by an
ABL 700 Copenhagen Blood Gas Analyzer (Radiometer
Copenhagen, Copenhagen, Denmark). Markers of bone
metabolism (bone alkaline phosphatase, osteocalcin, c-
telopeptide pyridinoline crosslinks of type I collagen, pro-
collagen type I N-propeptide) will be measured as detailed
in Cejka et al. [33]. All laboratory measurements, includ-
ing urinalyses, will be performed in an ISO 9001–2008
certified and ISO 15189-accredited clinical laboratory at
the Medical University Vienna [http://www.kimcl.at].
Randomization and study visits
Subjects will attend the clinic for a regular visit and blood
draw. After a careful review of their medical historypatients who fulfill the inclusion criteria will be contacted
and informed about the study protocol. Patients who
agree to participate in the study will be invited to a further
blood work-up to ensure that metabolic acidosis is chronic
rather than a one-time imbalance of the acid–base status.
After obtaining written informed consent (day 0) each pa-
tient will be randomized 1:1 either to the treatment group
or the control group (Figure 1). Subjects will be stratified
for age >60 years and ≤60 years [34], presence of diabetes
mellitus (yes/no) [35], severe chronic metabolic acidosis
(serum HCO3
- <18 mmol/L) versus moderate metabolic
acidosis (serum HCO3
- ≥18 mmol/L), and for previous
alkali treatment (yes/no). Previous alkali treatment is de-
fined as being continued for longer than 6 months (>25%
of the treatment period of the planned study) and serum
HCO3
- ≥20 mmol/L on more than 75% of measurements.
Stratified randomization will be carried out using the
web-based randomizer program provided by the Medical
University of Vienna [https://www.meduniwien.ac.at/
randomizer/web/login.php]. We use the minimization
method with a preferred treatment probability of 0.9, and
a combination depth of 2.0, to guarantee that treatment
allocation is balanced in all levels of the stratification
factors, as well as in all pairwise combinations of stratifi-
cation factors. After randomization, subjects will receive
either the high dose of sodium bicarbonate or, if neces-
sary, a low-dose rescue therapy with sodium bicarbonate.
Each study visit consists of a fasting blood draw (last food
intake including the study medication should be at least
8 hours before) and urinalysis, measurement of vital signs,
and assessment of changes in concomitant medication and
adverse events (Table 1). At the beginning of the study a
physical examination will be done and body weight and
height will be assessed. Study visits will be performed at
weeks 4, 8, 12, 20, 29, 38, 47, 60, 73, 86, and 104.
Intervention
The initial and the maintenance dose for the interven-
tion group will be determined based on the baseline
HCO3
- level and the levels measured during follow up
visits. Based on pilot data we expect the daily dose for
the intervention group to vary between two and six cap-
sules of Nephrotrans® 840 mg (1,680 to 5,040 mg sodium
bicarbonate per day). In the case of HCO3
- lower than
19 mmol/L at the baseline visit, or during follow up,
subjects randomized to the control group will receive
rescue therapy. We expect the daily dose to be zero to
three capsules of Nephrotrans® 840 mg (0 to 2,520 mg
sodium bicarbonate per day) for the control group. After
each study visit the study drug can be down- and up-
titrated according to the actual HCO3
- level and the re-
spective target value, as pre-specified at randomization,
by means of the suggested treatment algorithm (Table 2A
and B). However, due to intra-individual differences in
Figure 1 Study design. *Two consecutive measurements at least 1 day apart. CKD, chronic kidney disease.
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The primary outcome is renal function and will be mea-
sured by means of eGFR, calculated according to the 4-
variable-MDRD Study equation [36].
Secondary outcomes are death, and the need for renal re-
placement therapy (RRT) (patients with renal transplant-
ation, hemodialysis, peritoneal dialysis, and subjects who
are in need of RRT, but personally elect not to start it). The
need for RRT will be clinically evaluated, including moni-
toring of uremic symptoms (nausea and/or vomiting,
fatigue, deterioration in nutritional status and significant
weight loss, neuropathy, encephalopathy, or psychic distur-
bances), blood and fluid disturbances (volume overload,
malignant hypertension, anemia, bleeding diathesis, pleu-
ritis and/or pericarditis), and significant electrolyte imbal-
ances. A further secondary outcome is the percent change
in markers of bone metabolism (bone alkaline phos-
phatase, osteocalcin, c-telopeptide pyridinoline crosslinks
of type I collagen, and procollagen type I N-propeptide)
across groups.
Sample size
Assuming equal baseline levels of eGFR between the two
study groups, a clinically relevant difference of 5 ml in
eGFR after 2 years, and an estimated standard deviation of
12 ml for the change in eGFR after 2 years (pilot data,
Figure 2), an independent sample t-test with a sample size
of 2 × 100 patients will give 80% power to reach statistical
significance at a two-sided significance level of 5%.
Statistical methods
The intention-to-treat population will be used for statis-
tical analysis. The primary analysis focuses on the esti-
mated treatment effect at 2 years (difference between
the two groups in eGFR after two years), which will be
provided as the point estimate at the expected differ-
ence, 95% confidence interval and P-value. Mortality ofpatients or other reasons for dropout will be addressed
by jointly modeling longitudinal eGFR and time to death
using an appropriate joint model for longitudinal and
time-to-event outcome [37]. In the longitudinal part of
this model, a linear mixed model will be used with the
repeated eGFR measurements as outcome values, and
including as fixed factors treatment group, all stratifica-
tion criteria (age, diabetes, severity of acidosis, previous
alkali treatment), the eGFR baseline value and time since
start of treatment, and a random intercept. An inter-
action effect (product term) of the treatment group and
the time since start of treatment will also be included.
Graphical diagnostic tools (residual plots) will be used to
confirm the adequacy of model assumptions. A second-
ary outcome is time to death, compared between the
treatment groups, which will also be estimated by the
joint modeling approach. The time up to the point of
need of RRT will be compared between the two treat-
ment groups, accounting for death as a competing risk,
by modeling the cumulative incidence function [38], in-
cluding treatment group and the covariates age, diabetes,
severity of acidosis and baseline eGFR. Percent change
(from baseline to week 20 and baseline to week 104,
respectively) in markers of bone metabolism will be ana-
lyzed by analysis of covariance, to adjust for sex, age,
change in renal function, and baseline values of the bone
markers. The incidence of serious adverse events will be
reported and compared between groups using the
chi-squared test. Baseline parameters (etiology of CKD,
relevant medical disease, age, gender, concomitant medi-
cation, blood pressure, number of antihypertensive med-
ications, and laboratory measurements) will be analyzed
descriptively for the interventional and control group,
respectively. SAS (Version 9.3, SAS Institute Inc., Cary,
NC, USA, 2011) will be used for data management and
analysis, and R 2.12.2/package JM [37] will be used for
the main outcome analysis.
Discussion
In 1931 Lyon et al. described for the first time the sim-
ple approach of compensating metabolic acid excess in a
Table 1 Visit and assessment schedule
Screening period (4 weeks) Treatment period (0 to 24 months)
Day 0 Week 4 Week 8 Week 12 Week 20 Week 29 Week 38 Week 47 Week 60 Week 73 Week 86 Week 104
(± 2 days) (± 2 days) (± 2 days) (± 5 days) (± 5 days) (± 5 days) (± 5 days) (± 10 days) (± 10 days) (± 10 days) (± 10 days)
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13
Informed consent x
Inclusion/exclusion criteria x x
Randomization x
Medical history x x
Concomitant medication x x x x x x x x x x x x
Physical examination x x
Body weight and height x x
Vital signs (BP, PR) x x x x x x x x x x x x
Laboratory test x x x x x x x x x x x x x
Laboratory test: bone markers x x x
Biobank sample x x x x x
Urinalysis x x x x x x x x x x x x x
24-hour urine collection xa xa x x x x
Urine pregnancy testb x x x x x x x x x x x x
Adverse events x x x x x x x x x x














Table 2 Study drug up- and down-titration
Daily sodium bicarbonate (Nephrotrans® 840 mg) dosage
(A) Baseline treatment algorithm Investigational group Control group
Mean HCO3
- of two measurements
<18 mmol/L 5,040 mg (2 capsules TID) 2,520 mg (1 capsule TID)
18 to 19 mmol/L 4,200 mg (2 capsules BID, 1 capsule QD) 1,680 mg (1 capsule BID)
19.1 to 20.0 mmol/L 2,520 mg (1 capsule TID) Monitor
>20 mmol/L 1,680 mg (1 capsule BID)
(B) Follow-up visit treatment algorithm Investigational group and control group
Difference to target HCO3
- level
−1 mmol/L Add 1,680 mg to the previous daily dosage (+1 capsule BID)
−2 mmol/L Add 3,360 mg to the previous daily dosage (+2 capsules BID)
≤ −3 mmol/L Add 5,040 mg to the previous daily dosage (+2 capsules TID)
+1 mmol/L Subduct 1,680 mg from the previous daily dosage (−2 capsules)
+2 mmol/L Subduct 3,360 mg from the previous daily dosage (−4 capsules)
≥ +3 mmol/L Subduct 5,040 mg from the previous daily dosage (−6 capsules)
QD, every day; BID, twice daily; TID, trice daily.
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an alkaline diet or substituting alkaline salts [39]. In
2012 the question of whether or not systematic treat-
ment of metabolic acidosis in CKD is indicated is still to
be addressed by the scientific community, due to the
paucity of acceptable evidence [40-42].
Indeed, patients with CKD comprise a difficult study
cohort in terms of sample size calculation and accurate
methodological planning, due to severe comorbidities
and increased mortality [25,43-47]. De Brito-Ashurst
et al. [28] tried to show that correcting metabolic acid-
osis stabilizes renal function in patients with CKD stage
IV. In the open-label study the control group had a
significantly greater decline in creatinine clearance
(5.93 mL/min) compared to the treatment group
(1.88 mL/min) after 2 years. Furthermore, subjects in
the treatment group presented with significantly slower
progression of CKD (defined as creatinine clearance loss
>3 mL/min/year) (9% versus 45% in the control group).
However, critical issues concerning the study method-
ology are that first, rapid progression and development
of ESRD are competing endpoints, and second, the way
this was handled in the data analysis is unclear. They
stated that ‘the rate of decline of creatinine clearance
was similar between the two groups up to 12 months of
follow-up because of dropout of 17 patients of the con-
trol group who had rapid decline and reached ESRD be-
tween 6 and 12 months’. However, only 15 dropouts are
depicted in the respective Kaplan-Meier curve (Figure
three in de Brito-Ashurst et al. [28]) between months 6
and 12. This might be the source of confounding and
can be avoided by using a more appropriate competing
endpoint analysis [48]. Further, the need of that add-
itional endpoint is questionable, because subjects withrapid decline in renal function essentially reach ESRD at
some point in time. Also, the control group was treated
with ‘standard care’ with no further explanation whether
that protocol included sodium bicarbonate supplementa-
tion. If this was not the case, the administration of pla-
cebo in the control group might have been indicated.
Mahajan et al. [26] recently compared the effect of so-
dium bicarbonate, sodium chloride and placebo on GFR
in patients with early hypertensive nephropathy over
5 years. This was a randomized blinded trial in patients
with CKD stage II, hypertension and albuminuria (200
to 2,000 mg/g creatinine), but normal plasma total car-
bon dioxide levels (equivalent to serum bicarbonate con-
centrations). Although the study population showed no
biochemical signs of metabolic acidosis the supplementa-
tion of sodium bicarbonate was beneficial in terms of
renal function: the rate of change of eGFR in the sodium
bicarbonate group was −1.47 ± 0.19 compared to −2.13 ±
0.19 (P < 0.014) in the placebo group and −2.05 ±
0.19 mL/min/1.73 m2 per year (P < 0.029) in the sodium
chloride group. This gives good evidence that sodium bi-
carbonate supplementation provides positive effects on
renal function on the one hand, but on the other only for
that very selected cohort of patients with well-preserved
renal function and albuminuria. Unfortunately, one can-
not conclude that in patients with advanced renal injury
and low GFR the therapeutic intervention would lead to
the same outcome.
Another study, although designed to investigate the
mechanism of preventing renal injury by oral sodium cit-
rate, showed that treating metabolic acidosis in patients
with CKD slows the decline of renal function (sodium
citrate versus control: eGFR −1.60 ± 0.13 versus −3.79 ±
0.30 mL/min/1.73 m2 per year, P < 0.0001) [27]. We
Figure 2 Cohort analyzed to calculate the sample size. CKD,
chronic kidney disease; eGFR, estimated glomerular filtration rate.
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our study patients due to the known increased aluminum
absorption in combination with sodium citrate [49].
Furthermore, studies in animals and humans suggest
that an acid-reduced diet may improve kidney function
equally to supplementation with bicarbonate by means
of tablets [50]. However, base-inducing diets predomin-
antly include vegetables and fruits, which contain high
amounts of potassium. In the long term, however, sub-
jects with preserved renal function, who are not prone
to hyperkalemia, might benefit tremendously from base-
rich diets over the commonly preferred acid-inducing
diet of our society [51,52].
With regard to the presented study protocol we opted
for an open-label approach, predominantly because to
some extent sodium bicarbonate is included in standard
routine care. Withdrawing that therapeutic intervention
from study subjects could be deemed unethical. Aside
from ethical reasons, the dose of the study drug in the
interventional group is not fixed and administering an
average amount of placebo tablets to the control group is
also questionable. Moreover, given the relatively narrow
range of suggested optimal HCO3
- levels and the distinct
between-subject difference in response to treatment,
blood levels have to be maintained regularly. Blinding ofthese laboratory results would have caused a dispropor-
tionately high amount of effort and cost compared to its
benefits.
With regard to the intervention itself, sodium bicar-
bonate supplementation represents a simple therapeutic
maneuver to restore acid–base balance in CKD patients.
Few adverse events are reported in combination with oral
sodium bicarbonate supplementation. Abdominal bloating
would appear to be innocuous as it can be avoided by div-
iding the daily dosage into several smaller portions.
A mentionable concern is the additional sodium con-
sumption evoked by the study medication. For each
100 mg of sodium bicarbonate the additional sodium in-
take is approximately 27.4 mg. Dietary sodium intake is
known to negatively influence arterial hypertension,
therefore, blood pressure should be carefully monitored
and if necessary, treated with antihypertensive agents.
Notably, none of the studies performed in humans have
noticed worsening of arterial hypertension in relation to
the sodium bicarbonate supplementation. Nevertheless,
this adverse event is reported for animal experiments
[18]. However, former investigations suggested that the
blood pressure-elevating effect is led by chloride and not
by sodium. Although sodium retention and weight gain
was similar across study groups an increase in arterial
blood pressure could not be detected in subjects inges-
ting additional dietary sodium bound to an alternative
anion than chloride [53-55]. In addition, there is a theor-
etical concern that long-term sodium bicarbonate intake
may favor the development of calcium phosphate- and
magnesium phosphate stones in the urinary tract, but so
far this has not been observed in humans.
A single study was performed in cultured cells and
uremic rats to investigate whether sodium bicarbonate
supplementation affects the pathologic calcification of
blood vessels. De Solis et al. reported that acid media
prevented calcification of cultured vascular smooth
muscle cells, and that uremic rats treated with sodium
bicarbonate had a significantly higher aortic calcification
index [56]. Given all the evidence of positive alteration
by the supplementation of sodium bicarbonate, these
concerns need to be kept in mind, and blood pressure
will be closely monitored during the follow up period.
Taken together, previous studies, including observa-
tional and animal studies, give confidence that simply
supplementing sodium bicarbonate in patients with
CKD of any degree could positively alter decline in renal
function. Possible adverse events are within the accept-
able ratio of benefit to risk, however, adverse events will
be followed closely in the study participants.
In summary, we believe that a clinical investigation to
elucidate the effect of sodium bicarbonate supplementa-
tion in patients with metabolic acidosis and advanced
CKD is of urgent need to develop a proper treatment
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the prognosis for each individual patient, but also help
to decrease health care expenses, as sodium bicarbonate
represents a relatively cheap treatment option.
Trial status
Recruitment is planned to start in October 2013.
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